quintilesIMS
Articles/ Healthcare/ UK & Europe/ Views and analysis
Will UK patients get access to novel drugs?
Andrew McConaghie
NHS England, NICE, Quintiles IMS Market Access Summit, quintilesIMS, UK market access
0 Comment
Access to new medicines is not high up the list of priorities for NHS England, but pharma must seize opportunities to promote innovation uptake.
Oncology/ Partner Content/ Partner content/ Press releases/ Quintiles - ContentIO/ R&D
Beyond Immunotherapies
Julia Marsteller
cancer, clinical trials, immunotherapy, pharma, quintilesIMS
Latest innovations emerging from immunotherapy research
Oncology/ Partner Content/ Partner content/ Press releases/ Quintiles - ContentIO/ R&D
Managing Multi-Arm Studies in an Evolving Immuno-Oncology Landscape
Julia Marsteller
cancer, clinical trials, immunotherapy, pharma, quintilesIMS
Collaborate with CROs and sites to help minimize risks
Market Access/ Partner Content/ Pharma Market Access/ Press releases
Orphan medicines, advances, access and affordability
Adam Jeffery
market access, NHS England, NICE, QALY, quintilesIMS, rare disease, STP, UK
0 Comment
The top three benefits to commercial outsourcing in pharma
Craig Sharp
commercial outsourcing, pharma, quintilesIMS
0 Comment
Insights/ Sales and Marketing/ Whitepapers
Seizing the potential of commercial outsourcing in the pharmaceutical sector
Louise Bellamy
commercial outsourcing, market access, pharma, quintilesIMS
0 Comment
Articles/ Brexit/ Pharma Market Access/ R&D/ UK & Europe/ Views and analysis
Getting it right: the UK’s pathway for 2017
Linda Banks
Brexit, European Patent Convention, HTA, market access, NICE, quintilesIMS, UK
0 Comment
The implications for global pharma HQs and what the UK needs to do.
Insights/ Sales and Marketing/ Sales and Marketing/ Slider in whitepapers/ Whitepapers